359 related articles for article (PubMed ID: 26085527)
21. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.
Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R
J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic KRas mobility in the membrane and signaling response.
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():109-113. PubMed ID: 29499269
[TBL] [Abstract][Full Text] [Related]
23. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
24. A New View of Ras Isoforms in Cancers.
Nussinov R; Tsai CJ; Chakrabarti M; Jang H
Cancer Res; 2016 Jan; 76(1):18-23. PubMed ID: 26659836
[TBL] [Abstract][Full Text] [Related]
25. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
27. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
28. K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract][Full Text] [Related]
29. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
30. KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner.
Agamasu C; Ghirlando R; Taylor T; Messing S; Tran TH; Bindu L; Tonelli M; Nissley DV; McCormick F; Stephen AG
Biophys J; 2019 Mar; 116(6):1049-1063. PubMed ID: 30846362
[TBL] [Abstract][Full Text] [Related]
31. The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.
Chen Z; Chen M; Fu Y; Zhang J
Pathol Res Pract; 2023 Aug; 248():154603. PubMed ID: 37356222
[TBL] [Abstract][Full Text] [Related]
32. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.
Oliva JL; Zarich N; Martínez N; Jorge R; Castrillo A; Azañedo M; García-Vargas S; Gutiérrez-Eisman S; Juarranz A; Boscá L; Gutkind JS; Rojas JM
J Biol Chem; 2004 Aug; 279(32):33480-91. PubMed ID: 15181015
[TBL] [Abstract][Full Text] [Related]
33. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
34. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
35. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
36. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
[TBL] [Abstract][Full Text] [Related]
37. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
38. Both the C-terminal polylysine region and the farnesylation of K-RasB are important for its specific interaction with calmodulin.
Wu LJ; Xu LR; Liao JM; Chen J; Liang Y
PLoS One; 2011; 6(7):e21929. PubMed ID: 21750741
[TBL] [Abstract][Full Text] [Related]
39. The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function.
Abdelkarim H; Banerjee A; Grudzien P; Leschinsky N; Abushaer M; Gaponenko V
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739603
[TBL] [Abstract][Full Text] [Related]
40. Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit.
Wang G; Zhang M; Jang H; Lu S; Lin S; Chen G; Nussinov R; Zhang J; Gaponenko V
Biochemistry; 2018 Mar; 57(12):1917-1928. PubMed ID: 29494137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
